a528e2fc-f91a-4835-a0f6-0a49400a40a2
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.310
- HEDGEHOG_SIGNALING+0.260
- APICAL_JUNCTION+0.240
- P53_PATHWAY+0.230
- APICAL_SURFACE+0.100
- MYC_TARGETS_V2+0.080
- MYOGENESIS+0.060
- BILE_ACID_METABOLISM+0.040
- ESTROGEN_RESPONSE_EARLY+0.040
- PEROXISOME+0.040
Top 10 suppressed
- E2F_TARGETS-0.430
- G2M_CHECKPOINT-0.350
- TNFA_SIGNALING_VIA_NFKB-0.330
- PROTEIN_SECRETION-0.320
- MTORC1_SIGNALING-0.300
- IL6_JAK_STAT3_SIGNALING-0.290
- MYC_TARGETS_V1-0.270
- UV_RESPONSE_UP-0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.260
- UNFOLDED_PROTEIN_RESPONSE-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | f17e12f0-54ed-4dc2-ab7e-22a1f90e1405 | — | — | 0.837 |
| 2 | SRR4195667 | — | — | 0.800 |
| 3 | ERR2208935 | — | — | 0.793 |
| 4 | TCGA-D8-A3Z5-01A-41R-A24H-07 | — | A | 0.786 |
| 5 | MBCProject_0719_T1_RNA | — | A | 0.785 |
| 6 | MDT-AP-1120 | Med | Medulloblastoma | 0.783 |
| 7 | TCGA-W8-A86G-01A-21R-A36F-07 | — | A | 0.783 |
| 8 | MDT-AP-0830 | Med | Medulloblastoma | 0.783 |
| 9 | SRR1313116 | — | A | 0.773 |
| 10 | 8683d8f5-bba5-40a1-a460-ad6183d2302b | — | — | 0.770 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.080 | Idelalisib | — uncovered |
| MYOGENESIS | 0.060 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |